The Effect of Anakinra on Insulin Secretion

Inclusion Criteria: * Impaired glucose tolerance assessed by oral glucose tolerance test and/or impaired fasting glucose ( ≥ 5.6 mmol/L) and/or HbA1c levels of 5.7-6.4% * BMI \>25 kg/m2 * Age 40-70 years Exclusion Criteria: * Known diabetes mellitus * Fasting plasma glucose ≥ 7.0 mmol/L or HbA1c ≥ 6.5% * Immunodeficiency or immunosuppressive treatment (including TNFα blocking agents and corticosteroids) * Use of anti-inflammatory drugs ( including corticosteroids and non steroidal anti-inflammatory drugs, 100 mg or less of aspirin is allowed) * Signs of current infection (fever, C-reactive protein \>30 mmol/L, treatment with antibiotics, previous or current diagnosis of tuberculosis) * A history of recurrent infections * Pregnancy or breastfeeding (contraception of at least 3 months before inclusion is required) * Liver disease defined as aspartate aminotransferase or alanine aminotransferase level of more than three times the upper limit of normal range * Renal disease defined as MDRD \< 60 ml/min/1.73m2 * Neutropenia \< 2x 109/L * Inability to understand the nature and extent of the trial and the procedures required. * Any medical condition that might interfere with the current study protocol * Participation in a drug trial within 60 days prior to the first dose